duloxetine

(redirected from Cymbalta)
Also found in: Medical.

du·lox·e·tine

 (də-lŏk′sĭ-tēn′)
n.
A drug of the SNRI class, C18H19NOS, used in its hydrochloride form to treat depression, anxiety, fibromyalgia, and diabetic neuropathy.

[Perhaps du(al) (from its being a dual serotonin and norepinephrine reuptake inhibitor) + (flu)oxetine.]
Translations

duloxetine

n duloxetina
Mentioned in ?
References in periodicals archive ?
For soma patients it may also include medications such as duloxetine (Cymbalta, Eli Lilly), milnacipran (Savella, Allergan), and pregabalin (Lyrica, Pfizer).
During his years at Lilly, Brown has helped bring many blockbuster products to market, including Taltz, Cialis and Cymbalta, as well as overseeing the launch of seven new chemical entities across a range of therapeutic categories, including dermatology.
The antidepressant duloxetine (Cymbalta) is being studied by the Cymbalta Pregnancy Registry (866-814-6975).
Commonly ordered medications are Abilify, Advair Diskus, Celebrex, Crestor, Cymbalta, Entocort, Januvia, Lyrica, Nexium, Pradaxa, Premarin, Vytorin, and Xarelto.
Duloxetine Delayed-release Capsules are AB rated to Eli Lilly's Cymbalta for the treatment of major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathy and chronic musculoskeletal disorder.
Previously, Mark was the Chief Medical Officer at Neuronetics, Inc., where he was responsible for the development and approval of the NeuroStar transcranial magnetic stimulation system for the treatment of pharmacoresistant depression, and Medical Director at Lilly Research Labs where he was responsible for the development of CNS drugs from early phase to post-market commercialization and oversaw the development and approval of Cymbalta for major depression.
D had diagnosed me with clinical depression and anxiety disorder and prescribed a daily dose of 60 mg of Cymbalta, an antidepressant, and 1/4 of a 2-mg tablet of Rivotril, an antiseizure sedative used to treat anxiety.
Fourteen different drugs topped the $1 billion mark in 2013, among them well-known names like Nexium, Crestor and Cymbalta. This information published as part of a new dataset released on April 30 by the Centers for Medicare and Medicaid Services (CMS).
patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.8 million) continue to negatively impact results.
Indianapolis-based Lilly is counting on new drugs like Trulicity to replace falling revenue from blockbusters like the antidepressant Cymbalta, which is facing cheaper generic competition after the expiration of its patent.
[ClickPress, Fri Jun 20 2014] Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023